These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
879 related articles for article (PubMed ID: 25774769)
1. Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease--The Shifting Treatment Paradigm. Wilkie M; Finch S; Schembri S COPD; 2015; 12(5):582-90. PubMed ID: 25774769 [TBL] [Abstract][Full Text] [Related]
2. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019 [TBL] [Abstract][Full Text] [Related]
3. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes. Hizawa N Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659 [TBL] [Abstract][Full Text] [Related]
5. Role of Long-Acting Muscarinic Antagonist/Long-Acting β Petite SE Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560 [TBL] [Abstract][Full Text] [Related]
6. Effects of inhaled corticosteroids /long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: A nationwide cohort study 2002-2013. Cho KH; Kim YS; Linton JA; Nam CM; Choi Y; Park EC Respir Med; 2017 Sep; 130():75-84. PubMed ID: 29206637 [TBL] [Abstract][Full Text] [Related]
7. Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids. Liao PA; Pan SW; Chen CY; Deng CY; Dong YH Int J Chron Obstruct Pulmon Dis; 2023; 18():553-563. PubMed ID: 37069844 [TBL] [Abstract][Full Text] [Related]
8. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study. Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047 [TBL] [Abstract][Full Text] [Related]
9. Stepwise management of COPD: What is next after bronchodilation? Miravitlles M; Matsunaga K; Dreher M Ther Adv Respir Dis; 2023; 17():17534666231208630. PubMed ID: 37936381 [TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Long-Acting Beta Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405 [TBL] [Abstract][Full Text] [Related]
11. A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease. D'Urzo A; Donohue JF; Kardos P; Miravitlles M; Price D Expert Opin Pharmacother; 2015; 16(12):1845-60. PubMed ID: 26194213 [TBL] [Abstract][Full Text] [Related]
12. Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study. Wurst KE; Shukla A; Muellerova H; Davis KJ COPD; 2014 Sep; 11(5):521-30. PubMed ID: 24945236 [TBL] [Abstract][Full Text] [Related]
13. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids. Asche CV; Leader S; Plauschinat C; Raparla S; Yan M; Ye X; Young D Int J Chron Obstruct Pulmon Dis; 2012; 7():201-9. PubMed ID: 22500120 [TBL] [Abstract][Full Text] [Related]
14. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Price D; West D; Brusselle G; Gruffydd-Jones K; Jones R; Miravitlles M; Rossi A; Hutton C; Ashton VL; Stewart R; Bichel K Int J Chron Obstruct Pulmon Dis; 2014; 9():889-904. PubMed ID: 25210450 [TBL] [Abstract][Full Text] [Related]
15. Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. Nici L; Mammen MJ; Charbek E; Alexander PE; Au DH; Boyd CM; Criner GJ; Donaldson GC; Dreher M; Fan VS; Gershon AS; Han MK; Krishnan JA; Martinez FJ; Meek PM; Morgan M; Polkey MI; Puhan MA; Sadatsafavi M; Sin DD; Washko GR; Wedzicha JA; Aaron SD Am J Respir Crit Care Med; 2020 May; 201(9):e56-e69. PubMed ID: 32283960 [No Abstract] [Full Text] [Related]
16. Can Assessment of Disease Burden Prior to Changes in Initial COPD Maintenance Treatment Provide Insight into Remaining Unmet Needs? A Retrospective Database Study in UK Primary Care. Landis SH; Wurst K; Le HV; Bonar K; Punekar YS COPD; 2017 Feb; 14(1):80-85. PubMed ID: 27819513 [TBL] [Abstract][Full Text] [Related]
17. Long-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta-analysis. Horita N; Miyazawa N; Tomaru K; Inoue M; Kaneko T Respirology; 2015 Nov; 20(8):1153-9. PubMed ID: 26235837 [TBL] [Abstract][Full Text] [Related]
18. Inhaled treatment for chronic obstructive pulmonary disease: what's new and how does it fit? Currie GP; Lipworth BJ QJM; 2016 Aug; 109(8):505-12. PubMed ID: 26559079 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Hertel N; Kotchie RW; Samyshkin Y; Radford M; Humphreys S; Jameson K Int J Chron Obstruct Pulmon Dis; 2012; 7():183-99. PubMed ID: 22500119 [TBL] [Abstract][Full Text] [Related]
20. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials. Lai CC; Chen CH; Lin CYH; Wang CY; Wang YH Int J Chron Obstruct Pulmon Dis; 2019; 14():1539-1548. PubMed ID: 31371939 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]